Novartis AG - About Blood Disorders

CHICAGO (Reuters) - A second pivotal trial of ruxolitinib, developed by Incyte Corp and Novartis, met its goal of showing that the drug significantly reduces spleen size in myelofibrosis patients.The rare, but potentially deadly, blood cancer is characterized by bone marrow failure, ...

ZURICH (Reuters) - Novartis AG's blood cancer drug INC424 could rake in annual sales of $1 billion, the group's head of oncology told Reuters on Tuesday, in a boost to the Swiss drugmaker's cancer pipeline."We believe it can become a very reasonable ...

Myelofibrosis is a blood cancer characterized by bone marrow failure, enlarged spleen, poor quality of life and shortened survival[1] * Phase I/II data published in NEJM demonstrate clinical benefits of JAK1 and JAK2 inhibitor INC424, including reduction of spleen size and alleviation ...

Myelofibrosis is a cancer characterized by bone marrow failure, enlarged spleen, poor quality of life and shortened survival Phase I/II data show Incyte's JAK1 and JAK2 inhibitor INCB18424 demonstrates durable clinical benefits including reduction of spleen size and alleviation of debilitating constitutional ...

As only the second JAK inhibitor to enter phase III trials, Incyte's (INCY) INCB18424 has already attracted a fair amount of attention. This attention turned into hard cash Wednesday with a chunky licensing deal struck with Novartis (NVS), which has bought ex-US ...

New data from the largest prospective trial in iron chelation demonstrate the efficacy and safety of Exjade(R) (deferasirox) in treating chronic transfusional iron overload, a potentially life-threatening condition for patients who have had multiple blood transfusions to treat underlying anemias, including beta-thalassemia ...

Topic: Novartis AG

Incyte, Novartis myelofibrosis trial meets goal

Novartis sees blood cancer drug as blockbuster

Novartis International AG (CH) - Novartis JAK inhibitor provides marked and durable clinical benefits in patients with myelofibrosis, a rare, life-threatening blood cancer

Phase I/II Data Published in New England Journal of Medicine Demonstrate that Incyte JAK Inhibitor, INCB18424, Provides Marked and Durable Clinical Benefits in Patients with Myelofibrosis, a Rare, Life-Threatening Blood Cancer

Novartis Deal Gives Incyte a Boost

Exjade Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial

Photo Gallery

From Around the Web

Video Gallery

Follow this Topic with...